Serum levels of LIGHT in MS

Area of Science:

• Immunology
• Genetics
• Neurology

Background:

• A genome-wide association study identified a polymorphism in the LIGHT gene associated with increased multiple sclerosis (MS) risk.
• The specific polymorphism rs1077667 was implicated in MS susceptibility.

Purpose of the Study:

• To determine if serum LIGHT levels are influenced by the rs1077667 polymorphism.
• To investigate the correlation between serum LIGHT levels and multiple sclerosis disease activity.
• To assess the impact of natalizumab treatment on serum LIGHT levels in MS patients.

Main Methods:

• Serum LIGHT levels were measured in four distinct cohorts, including MS patients and healthy controls.
• Genotyping for the rs1077667 polymorphism was performed in relation to LIGHT serum levels.
• Comparisons were made between MS patients during relapse and remission, and with other neurological diseases.
• Longitudinal analysis of LIGHT levels was conducted before and after natalizumab treatment in MS patients.

Main Results:

• Individuals with the GG genotype of rs1077667 exhibited significantly lower serum LIGHT levels (p=0.02).
• Serum LIGHT levels were elevated in MS patients during relapse compared to healthy controls (p=0.00005) and those in remission (p=0.00006).
• Increased LIGHT levels were observed in MS patients compared to other neurological diseases (p=0.002) and inflammatory neurological conditions (p=0.00005).
• Treatment with natalizumab led to a significant decrease in serum LIGHT levels (p=0.001).

Conclusions:

• Lower serum LIGHT levels in GG genotype carriers, who have a higher MS risk, suggest a protective role for LIGHT.
• Elevated LIGHT levels during active MS indicate it may function to mitigate inflammation.
• Soluble LIGHT acts as an inhibitor of T-cell activation, potentially explaining its role in managing MS.